alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 21,476–21,500 of 27,146 studies marked Peer-reviewed (page 860 of 1086) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Association of residential neighborhood disadvantage with amyloid PET positivity among cognitively impaired individuals

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia Behavior & Socioeconomics of Aging 2026-01-29

Residence in the most disadvantaged neighborhoods may be associated with lower amyloid pathology in cognitively impaired individuals. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Both Targeted Mass Spectrometry and Flow Sorting Analysis Methods Detected the Decreased Serum Apolipoprotein E Level in Alzheimer's Disease Patients

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Molecular & Cellular Proteomics 2013-12-08

Apolipoprotein E (ApoE) polymorphism has been appreciated as a valuable predictor of Alzheimer disease (AD), and the associated ε4 allele has been recognized as an indicator of susceptibility to this disease. 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

O4–04–05: Geographical variation in dementia prevalence in Swedish twins: Using Bayesian inference to separate genetic and environmental effects

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2013-07-01

There is evidence of geographical variation in dementia[1], not all of which can be ascribed to genetic factors[2]. 1 key finding →

Participants: 568 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The association of neighborhood deprivation with sleepiness among cognitively normal older adults with and without subjective cognitive decline

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-12-01

Among the study population at large, there was a statistically significant association between ADI and ESS scores (β = 0.490, 95% CI [0.138, 0.842], p = 0.007). 5 key findings →

Participants: 81 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Development and validation of a predictive nomogram for mild cognitive impairment in middle-aged and elderly populations: A multi-module analysis integrating air quality and sociodemographic factors

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Alzheimer s Disease 2025-10-07

The validated nomogram enables individualized MCI risk stratification, supporting targeted community prevention strategies. 2 key findings →

Participants: 7,702 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Interaction between DNA methylation and neighborhood disadvantage may impact risk for cognitive decline among Mexican Americans enrolled in the Health and Aging Brain Study – Health Disparities (HABS‐HD) Cohort

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2023-12-01

The lack of significant results for moderation effects of the targeted epigenetic markers in our pilot study were likely due to the small sample size. 5 key findings →

Participants: 812 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Agricultural pesticide use and Alzheimer’s disease dementia prevalence across US counties in a mixed supervised–unsupervised analysis

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Scientific Reports 2026-06-11

Agricultural pesticide use represents one of the most geographically patterned environmental systems, yet most prior research has focused largely on individual compounds rather than correlated exposure regimes. 3 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Characterizing Exposure to Traffic‐Related Air Pollution in a Diverse Alzheimer’s Disease Research Center Cohort

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2024-12-01

Preliminary analysis indicates significant differences in location, ethnoracial background, ADI, and TRAP exposure amongst UCD ADRC participants. 5 key findings →

Participants: 985 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Does Neighborhood Disadvantage Moderate the Relationship between Apolipoprotein E Status and Cognitive Functioning?

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-12-01

Environmental factors like neighborhood disadvantage are also associated with cognitive decline, however, few studies have integrated this with APOE research. 5 key findings →

Participants: 190 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Experimental Neurobiology 2025-02-28

Alzheimer disease (AD) diagnosis is confirmed using a medley of modalities, such as the detection of amyloid-β (Aβ) neuritic plaques and neurofibrillary tangles with positron electron tomography (PET) or the appraisal of irregularities in cognitive function with examinations. 3 key findings →

Participants: 53 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Storage-dependent variability in Alzheimer disease-related plasma biomarker results using the Fujirebio Lumipulse G1200 platform

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Neuropathology & Experimental Neurology 2025-09-17

Alzheimer disease plasma biomarkers have emerged as minimally invasive, cost-effective tools for early diagnosis and disease monitoring yet their stability under common "real world" pre-analytical conditions remains incompletely characterized. 3 key findings →

Participants: 12 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Development of a novel in‐house blood biomarker panel for early diagnosis of Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-12-01

We have successfully generated specific high affinity monoclonal antibodies against p -Tau217, p -Tau205, and N-terminus GFAP and have confirmed that these antibodies have the necessary specificity and sensitivity for the Simoa platform. 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

ApoE4 Upregulates GSK ‐3β to Aggravate Alzheimer‐Like Pathologies and Cognitive Impairment in Type 2 Diabetic Mice

✓ Peer-reviewed alzhub usefulness score 39 out of 100. CNS Neuroscience & Therapeutics 2025-09-01

We observed that GSK-3β activity was significantly upregulated in ApoE4 mice, accompanied by disruption of the insulin signaling pathway. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

APOE ε4 linked effects on clinical features and neuropathology in dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-10-01

In analyses of APOE ε4 carriers, dosage, and genetic risk score, APOE ε4 was associated with lower odds of fluctuating cognition and parkinsonism and higher odds of visual hallucinations. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Peruvian Population Empowers Discovery of a TREM2 Missense Variant in Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-12-01

Peruvian GWAS identified Amerindian ancestry specific exonic AD susceptibility variant p.H157Y. This variant has been previously reported as AD marker in Han Chinese populations with extreme effect size, but its rarity and contradictory findings in other groups suggest a potential ancestry‐specific effect. 4 key findings →

Participants: 567 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Predicting Alzheimer progression using EEG-based digital twins

✓ Peer-reviewed alzhub usefulness score 39 out of 100. npj Digital Medicine 2026-08-03

Early and accurate prognosis of Alzheimer’s disease (AD) remains limited by current biomarkers, which are often invasive, require expensive equipment, or fail to predict individual trajectories of cognitive decline. 2 key findings →

Participants: 459 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Exploring causal relationships between epigenetic age acceleration and Alzheimer’s disease: a bidirectional Mendelian randomization study

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Clinical Epigenetics 2025-10-03

Employing the random-effects IVW approach, we found that, as indicated by GrimAge, EAA was associated with an increased risk of AD (Odds Ratio [OR] = 1.025, 95% Confidence Interval [CI]: 1.006-1.044, p = 0.009). 5 key findings →

Participants: 63,926 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Associations of gut bacterial classes Clostridia and Deltaproteobacteria with type 2 diabetes and Alzheimer’s disease: A two-sample Mendelian randomization study

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Medicine 2026-05-15

Using a 2-sample Mendelian randomization (MR) approach, we evaluated MR evidence for genetically proxied effects of 10 pre-specified gut bacterial classes on type 2 diabetes mellitus (T2DM) and Alzheimer disease (AD), and assessed MR evidence for a direct genetically proxied effect of T2DM on AD. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed